SAINT-LOUIS, France & WEIL AM RHEIN, Germany June 27, 2023 –(BUSINESS WIRE)–Allecra Therapeutics (“Allecra”) announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for…Original Article
Allecra Therapeutics Submits New Drug Application to the U.S. FDA for Exblifep for the Treatment of Complicated Urinary Tract Infections
